When nerve meets muscle, biglycan seals the deal

Segmented synapses Synaptic structures in mice engineered to lack the protein biglycan (bottom row) appear discontinuous compared to the synaptic structures in normal mice (top). Credit: Credit: Fallon Lab/Brown University

A protein that has shown early promise in preventing the loss of muscle function in mouse models of Duchenne muscular dystrophy, has been found in a new study to be a key player in the process of joining nerves to muscles.

The protein biglycan needs to be present to stabilize synapses at the neuromuscular junction after they have formed, according to research led by Brown University that appears in the Feb. 14, 2012, issue of the Journal of Neruoscience.

"What neuromuscular junctions do second-by-second is essential for our brain to control movement and they are also important for the long-term health of both muscle and motor neurons," said Justin Fallon, profesor of neuroscience at Brown University and the paper's senior author. "A treatment that sustains or supports the synapse could promote the health of and muscle."

In previous work, Fallon, a member of the Brown Institute for , has shown that in mice with the same genetic mutation as Duchenne patients, biglycan promotes the activity of another , utrophin, that can significantly reduce the muscle degradation that patients suffer. Utrophin essentially takes over for , which is the protein Duchenne patients cannot produce. In 2010 Brown licensed Fallon's biglycan intellectual property to the Providence startup company Tivorsan Pharmaceuticals, which is working toward human trials of biglycan.

Last month the Muscular Dystrophy Association, which helped support Fallon's new study, gave Tivorsan a $1 million grant.

Now Fallon's research group has found another important role for biglycan. In the new multi-institutional study, lead author Alison Amenta and a team of other scientists found that biglycan binds and helps activate and target a receptor enzyme called MuSK, which works like a foreman or master regulator over other proteins that build and stabilize the neuromuscular junction.

Mice engineered to lack biglycan developed normal junctions at first, but by five weeks after birth their synapses became much more likely to break into fragmented shadows of their former selves. In experiments the scientists saw that up to 80 percent of synapses in biglycan-lacking mice were unstable.

Biglycan-lacking mice also showed other structural defects including misaligned neurotransmitter receptors and extra folds near synapses.

"We think it is most likely that these folds are remnants of previous synaptic sites," that have since withered, the authors wrote in the paper.

Amenta, Fallon, and their team also found that in mice lacking biglycan, levels of MuSK at neuromuscular junction were reduced by a factor of more than 10. In another experiment, they found that recombinant biglycan could rescue the stability of synaptic structures in model cell culture system.

Relevance to motor neuron diseases

The findings help set the stage for testing biglycan as a potential therapy in animal models of motor neuron disease, Fallon said.

"As an extracellular protein that can be delivered systemically that acts to stabilize the , we propose that biglycan could be a protein therapeutic for motor neuron diseases such as spinal muscular atrophy and amyotrophic lateral sclerosis, or ALS," Fallon said.

Related Stories

Recommended for you

What happens in our brain when we unlock a door?

3 hours ago

People who are unable to button up their jacket or who find it difficult to insert a key in lock suffer from a condition known as apraxia. This means that their motor skills have been impaired – as a result ...

Sport can help multiple sclerosis patients

6 hours ago

A study developed at the Miguel Hernández University of Elche (Spain) has preliminarily concluded that people with multiple sclerosis may reduce perceived fatigue and increase mobility through a series of ...

Obama's BRAIN initiative gets more than $300 million

11 hours ago

President Barack Obama's initiative to study the brain and improve treatment of conditions like Alzheimer's and autism was given a boost Tuesday with the announcement of more than $300 million in funds.

User comments

Adjust slider to filter visible comments by rank

Display comments: newest first

Jeddy_Mctedder
not rated yet Feb 14, 2012
this seems like a very big deal for developing potential 'smart' artificial limbs. i just don't see how eeg's are ever going to replace direct nerve output.

one day, they will figure out how to interface nerves unto digital chips in a manner that we observe nerves joined to muscle and we will do it by biologically manipulating the nerve to behave as if it were acting on the chip as if it were acting on the muslce. instead of the digital mechanical limb responding to a chip that is reading the output of your eeg, it will react to a chip that is reading the direct output of a neuron that is biologically wired to the chip as if the chip were a muscle.